Christine Willgoos, Special Counsel, Kramer Levin Naftalis & Frankel LLP to Speak at TKG’s event

New York, NY, January 23, 2017 --(PR.com)-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Christine Willgoos, Special Counsel, Kramer Levin Naftalis & Frankel LLP will speak at the Knowledge Group’s webcast entitled: “Resolving Patent Dispute Under BPCIA: Latest Developments and Strategies in 2017 Live Webcast.” This event is scheduled for February 14, 2017 from 3:00pm – 5:00pm (ET).

For further details, please visit: https://theknowledgegroup.org/event-homepage/?event_id=2111

About Christine Willgoos
Christine Willgoos litigates patent actions on behalf of pharmaceutical and biotechnology companies, leading trial and appellate teams in Hatch-Waxman and biologic drug litigation, often involving blockbuster drugs. Ms. Willgoos is an accomplished courtroom advocate with significant experience, including trials and appeals, preliminary injunctions, oral arguments and Markman hearings. She currently represents clients in cases concerning immunoassay technology, cancer drugs and multiple sclerosis drugs.

In addition to litigation, Ms. Willgoos counsels clients in business and legal matters relating to patent portfolios, including antitrust, patent prosecution, life cycle management and regulatory issues.

About Kramer Levin Naftalis & Frankel LLP
Kramer Levin Naftalis & Frankel LLP is a premier, full-service law firm with offices in New York, Silicon Valley and Paris. Firm lawyers are leading practitioners in their respective fields. The firm represents public and private companies – ranging from Global 1000 to middle-market and emerging growth companies – across a broad range of industries, as well as funds, institutions and individuals. For more information, please visit www.kramerlevin.com.

Event Synopsis:
Since its enactment as a component of the Patient Protection and Affordable Care Act on March 23, 2010, the Biologics Price Competition and Innovation Act (collectively known as BPCIA) has continually created an abbreviated approval pathway for producers of biological products. Primarily, the act caters for products which are “biosimilar” to or “interchangeable” with FDA-licensed biological products.

One of the most significant cases on BPCIA was the recently culminated Amgen-Sandoz Fight, which created a buzz on the industry and questioned how mandatory the “Patent Dance” is.

In a two-hour Live Webcast, a panel of thought leaders and practitioners assembled by The Knowledge Group will discuss the significant and latest issues surrounding the BPCIA. Aside from the updates and recent developments, they will further discuss 2017 strategies which will be helpful for both innovators and biosimilar applicants.

Key issues that will be covered in this course are:
· Supreme Court to hear the Amgen-Sandoz Fight
- Case Background
- The Neupogen® // Zarxio™ Biosimilar Dispute
- Questions the Supreme Court will address:
-- Is Patent Dance mandatory?
-- Is 180-day notice of commercial marketing mandatory? When must it be given?
- Implications of possible Supreme Court decision outcomes
· What open questions does the Supreme Court case not address?
· 2017 BPCIA Strategies Outlook

About The Knowledge Group /The Knowledge Congress Live Webcast Series

The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/